Massive Bio is a healthcare company leveraging AI (artificial intelligence) and other technologies to offer personalized oncology services.
Areas of Specialization
Massive Bio focuses primarily on three key healthcare areas: Oncology, Hematology, and Rare Diseases. Its commitment to Oncology and Hematology underscores its efforts to advance treatment and understanding of cancer and blood disorders. Its work in Rare Diseases shows its dedication to addressing less common but equally significant health conditions. Focusing on these areas, Massive Bio strives to improve patient outcomes and healthcare overall.
Massive Bio has grown beyond its local beginnings, with operations spanning continents. This expansion reflects the company’s commitment to making healthcare accessible worldwide.
Beyond its primary mission, Massive Bio provides several services to enhance access to clinical trials. These services include finding patients for trials, using AI for initial screening, and providing last-mile services to facilitate patient involvement smoothly. They also help select suitable trial sites and manage a command center for efficient trial oversight. These efforts underscore Massive Bio’s comprehensive approach to improving access to advanced treatments.
Massive Bio Capabilities Overview
As a leading healthcare technology company, Massive Bio specializes in personalized cancer treatment options. Its capabilities encompass precision medicine expertise, a wide range of treatment options, integration of artificial intelligence, telemedicine solutions, real-time clinical decision support, and patient relations. Leveraging these strengths, Massive Bio aims to revolutionize cancer care, offering patients worldwide tailored, advanced treatments. For more details, please click this link.
Massive Bio Sponsors
Massive Bio’s sponsors are essential collaborators supporting its mission to advance precision medicine in cancer care. These sponsors include pharmaceutical and biotech companies, academic and research institutions, patient relations organizations, healthcare providers, and technology innovators. Together, they help expand treatment options, conduct research, advocate for patients, integrate technology, and drive the transformative impact of personalized cancer care. More details please click this link.
Massive Bio & AstraZeneca Key Supply Information
Massive Bio’s partnership with AstraZeneca ensures reliable access to a diverse portfolio of cancer treatment medications. This collaboration facilitates timely supply, access to clinical trials, collaborative research, and educational support. Together, Massive Bio and AstraZeneca are advancing precision medicine and enhancing patient care. For more details please click this link.
Massive Bio Quality Assurance Documents
Massive Bio is fully compliant with EU GDPR and HIPAA requirements. You may access our consent forms, privacy policy, workflows and more.
Massive Bio Case Studies
Massive Bio shares a collection of impactful case studies demonstrating the success of personalized cancer care and precision medicine. These real-life stories show the positive outcomes of tailored treatment plans, advanced technologies, and a collaborative care approach. By sharing these case studies, Massive Bio aims to inspire hope and contribute to the ongoing improvement of personalized cancer care. For more details please click this link.
Selin Kurnaz, Co-Founder and CEO of Massive Bio, can be reached at [email protected]
Dr. Arturo Loaiza-Bonilla CMO of Massive Bio, can be reached at [email protected]
© 2024 Massive Bio. All rights reserved